The Latest News on FIP Research, the Bria Fund and Winn Feline Foundation
A recent media release announced licensure and commercial development of GC376, an antiviral FIP drug demonstrated to cure some cats with FIP. The research on the drug was coordinated between Dr. Yunjeong Kim of Kansas State University and Dr. Niels Pedersen of University of California-Davis.
Because of the research results, the Kansas State University of Commercialization coordinated a licensing agreement with Anivive Lifesciences, a California company with proprietary software able to advance discovery and development of new pet medications. While GC376 is still several years from release, if FDA app...
Many of you know that we held a fundraiser last month to recruit new FIP Patriots and raise money for future FIP research. Donations were received from new patriots and many experienced ones serving in our army to end FIP.
For the month of July, we raised $9395, almost a third of the amount needed to fund a $35,000 FIP study award! Thank you to everyone who participated and donated in July.
Previously, I shared news about the latest Bria Fund FIP supported project exploring genetics in relation to FIP. During the grant review process, another FIP related proposal was selected funded through Winn’s PetSmart Charities’ grant:
Principal Investigator: Gary Whittaker, PhD, Elizabeth Berliner, DVM; Cornell University, Grant ID: W18-007
Grant Amount: $24,307
Upper respiratory infections are an important cause of disease in cats, especially in animal shelters. While there are often multiple viruses and bacteria associated with upper respiratory infection, we have evidence that cats are infected with feline coronavirus in nasal and conjunctive (eye) swabs. Our study is designed to assess the importance of feline...